SCHEMBL4150397

SCHEMBL4150397

c1ccc(C(c2ccccc2)(c2ccccc2)n2nc(-c3ccc4ccccc4c3)c3ncccc32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 7/20 0.40
PIK3CD O00329 4/20 0.40
PIK3CA P42336 4/20 0.40
PIK3CB P42338 4/20 0.40
PIK3CG P48736 4/20 0.40
PRKDC P78527 4/20 0.40
ABL1 P00519 3/20 0.40
RIPK2 O43353 1/20 0.38
CYP17A1 P05093 1/20 0.35
CYP19A1 P11511 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
MAPK9 P45984 2/20 0.35
MAPK10 P53779 2/20 0.35
MAPK8 P45983 1/20 0.35
DCTPP1 Q9H773 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
MTOR P42345 2/20 0.34
EGFR P00533 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4140232 0.81 SRC (0.42) SRCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL4137276 0.81 SRC (0.37) SRCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL4140254 0.81 PDE4A (0.39) DCTPP1ADORA2AADORA1KDM4EALDH1A1
SCHEMBL4146205 0.79 ADORA2A (0.40) SRCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL13927626 0.78 SRC (0.49) SRCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL4159884 0.75 PIK3CD (0.38) SRCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL4137424 0.75 SRC (0.38) SRCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL5473131 0.73 BACE1 (0.36) CYP11B1CYP11B2ADORA2AKDM4ELMNA
SCHEMBL4137912 0.73 CYP11B1 (0.33) CYP11B1CYP11B2
SCHEMBL4149545 0.73 CYP11B1 (0.33) CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054397-A1 PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND OHI NORIHITO 2009-02-26 US disclosed
US-7429609-B2 Pyrazole compound and medicinal composition containing the same EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-09-30 US disclosed
US-20050261339-A1 Pyrazole compound and medicinal composition containing the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-24 US disclosed
US-20050208582-A1 Pyrazole compounds and pharmaceutical compositions comprising the compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-09-22 US disclosed
EP-1510516-A1 PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME Eisai Co., Ltd. (JP) 2005-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054397-A1 PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND CNKSR1, NR3C2, CSNK2B SRC 139/4885PIK3CD 2971/4885PIK3CA 2858/4885
US-20050261339-A1 Pyrazole compound and medicinal composition containing the same CNKSR1, NR3C2, CSNK2B SRC 151/4885PIK3CD 3161/4885PIK3CA 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.